2111 related articles for article (PubMed ID: 28899349)
1. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
2. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
5. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Zhao Y; Li H; Bai W; Liu J; Lv W; Sahu S; Guan S; Qin X; Wang W; Ren W; Mu W; Guo W; Gu S; Ma Y; Yin Z; Guo W; Wang W; Wang Y; Duran R; Fan D; Zhang Z; Han G
Int J Cancer; 2016 Aug; 139(4):928-37. PubMed ID: 27038145
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Lee S; Kang JH; Kim DY; Ahn SH; Park JY; Kim BK; Kim SU; Han KH
Hepatol Int; 2017 May; 11(3):292-299. PubMed ID: 28324324
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
9. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
14. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
Ohki T; Sato K; Yamagami M; Ito D; Yamada T; Kawanishi K; Kojima K; Seki M; Toda N; Tagawa K
Clin Drug Investig; 2015 Nov; 35(11):751-9. PubMed ID: 26446004
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
